Overview

A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus

Status:
RECRUITING
Trial end date:
2026-04-03
Target enrollment:
Participant gender:
Summary
This is an intervention, phase IV, single-arm study to assess the safety and efficacy of iGlarLixi in adult patients with Type 2 diabetes.
Phase:
PHASE4
Details
Lead Sponsor:
Sanofi
Treatments:
Insulin Glargine
lixisenatide